A Meta-Analysis of PTGS1 and PTGS2 Polymorphisms and NSAID Intake on the Risk of Developing Cancer

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Nagao, Mai ^a   Sato, Youichi ^a   Yamauchi, Aiko ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; NONSTEROID ANTIINFLAMMATORY AGENT;

ALLELE; ARTICLE; CANCER INCIDENCE; CANCER RISK; CARCINOGENESIS; COLORECTAL ADENOMA; COLORECTAL CANCER; ETHNICITY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HOMOZYGOSITY; HUMAN; INFLAMMATION; PTGS1 GENE; PTGS2 GENE; SENSITIVITY ANALYSIS; UNITED STATES;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FEMALE; HUMANS; MALE; NEOPLASMS; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PUBLICATION BIAS; RISK;

EID: 84881482918     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071126     Document Type: Article

References (20)

1. Smith WL, Garavito RM, DeWitt DL, (1996) Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and-2. J Biol Chem 271: 33157-33160.
2. Prescott SM, Fitzpatrick FA, (2000) Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta 1470: 69-78.
3. Mantovani A, Allavena P, Sica A, Balkwill F, (2008) Cancer-related inflammation. Nature 454: 436-444.
4. Hubner RA, Muir KR, Liu JF, Logan RF, Grainge MJ, et al. (2007) Polymorphisms in PTGS1, PTGS2 and IL-10 do not influence colorectal adenoma recurrence in the context of a randomized aspirin intervention trial. Int J Cancer 121: 2001-2004.
5. Gallicchio L, McSorley MA, Newschaffer CJ, Thuita LW, Huang HY, et al. (2006) Nonsteroidal antiinflammatory drugs, cyclooxygenase polymorphisms, and the risk of developing breast carcinoma among women with benign breast disease. Cancer 106: 1443-1452.
6. Ulrich CM, Bigler J, Sparks R, Whitton J, Sibert JG, et al. (2004) Polymorphisms in PTGS1 (= COX-1) and risk of colorectal polyps. Cancer Epidemiol Biomarkers Prev 13: 889-893.
7. Lurie G, Terry KL, Wilkens LR, Thompson PJ, McDuffie KE, et al. (2010) Pooled analysis of the association of PTGS2 rs5275 polymorphism and NSAID use with invasive ovarian carcinoma risk. Cancer Causes Control 21: 1731-1741.
8. Andersen V, Ostergaard M, Christensen J, Overvad K, Tjønneland A, et al. (2009) Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study. BMC Cancer 9: 407. Available: http://www.biomedcentral.com/1471-2407/9/407. Accessed 8 September 2011.
9. Barry EL, Sansbury LB, Grau MV, Ali IU, Tsang S, et al. (2009) Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence-data from a randomized clinical trial. Cancer Epidemiol Biomarkers Prev 18: 2726-2733.
10. Gong Z, Bostick RM, Xie D, Hurley TG, Deng Z, et al. (2009) Genetic polymorphisms in the cyclooxygenase-1 and cyclooxygenase-2 genes and risk of colorectal adenoma. Int J Colorectal Dis 24: 647-654.
11. Vogel U, Christensen J, Wallin H, Friis S, Nexø BA, et al. (2008) Polymorphisms in genes involved in the inflammatory response and interaction with NSAID use or smoking in relation to lung cancer risk in a prospective study. Mutat Res 639: 89-100.
12. Vogel U, Christensen J, Wallin H, Friis S, Nexø BA, et al. (2007) Polymorphisms in COX-2, NSAID use and risk of basal cell carcinoma in a prospective study of Danes. Mutat Res 617: 138-146.
13. Vogel U, Christensen J, Nexø BA, Wallin H, Friis S, et al. (2006) Peroxisome proliferator-activated receptor-gamma2 Pro12Ala, interaction with alcohol intake and NSAID use, in relation to risk of breast cancer in a prospective study of Danes. Carcinogenesis 28: 427-434.
14. Daraei A, Salehi R, Mohamadhashem F, (2012) PTGS2 (COX2)-765G>C gene polymorphism and risk of sporadic colorectal cancer in Iranian population. Mol Biol Rep 39: 5219-5224.
15. Ulrich CM, Whitton J, Yu JH, Sibert J, Sparks R, et al. (2005) PTGS2 (COX-2)-765G>C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev 14: 616-619.
16. Cheng I, Liu X, Plummer SJ, Krumroy LM, Casey G, et al. (2007) COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Br J Cancer 97: 557-561.
17. Cao H, Xu Z, Long H, Li XQ, Li SL, (2010) The-765C allele of the cyclooxygenase-2 gene as a potential risk factor of colorectal cancer: a meta-analysis. Tohoku J Exp Med 222: 15-21.
18. Zhang X, Miao X, Tan W, Ning B, Liu Z, et al. (2005) Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology 129: 565-576.
19. Dong J, Dai J, Zhang M, Hu Z, Shen H, (2010) Potentially functional COX-2-1195G>A polymorphism increases the risk of digestive system cancers: a meta-analysis. J Gastroenterol Hepatol 25: 1042-1050.
20. Zhang XM, Zhong R, Liu L, Wang Y, Yuan JX, et al. (2011) Smoking and COX-2 functional polymorphisms interact to increase the risk of gastric cardia adenocarcinoma in Chinese population. PLoS One 6: e21894. Available: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0021894. Accessed 24 May 2013.